J&J's Ry­bre­vant-chemo com­bo shows pos­i­tive PFS da­ta in con­fir­ma­to­ry study

John­son & John­son’s Ry­bre­vant met its pri­ma­ry end­point in a Phase III con­fir­ma­to­ry study test­ing the drug on pa­tients with new­ly di­ag­nosed ad­vanced or metasta­t­ic non-small cell lung can­cer (NSCLC) with EGFR ex­on 20 in­ser­tion mu­ta­tions, the com­pa­ny said in a topline da­ta re­lease Mon­day.

J&J com­pared a com­bo of chemother­a­py and Ry­bre­vant, which was the first drug ap­proved for pa­tients with the mu­ta­tion, with just chemother­a­py in the PA­PIL­LON study. The com­bo showed a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment” in pro­gres­sion-free sur­vival, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER